Latest PARP inhibitor Stories
17 abstracts include data from: NORTH CHICAGO, Ill., May 11, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced 17 abstracts from studies of the company's oncology pipeline are being presented
MADRID, April 14, 2015 /PRNewswire/ -- - Combination of the anticancer drug PM1183 with PARP inhibitors and doxorubicin results in a synergistic
RnRMarketResearch.com adds “Market Research Report on Global and Chinese Olaparib (CAS 763113-22-0) Industry, 2009-2019” Latest Report to its store. Dallas,
SAN FRANCISCO, Nov.
Sales of Breast Cancer Therapies are Expected to Almost Double Through 2023, Fueled by Growth in Several Distinct Market Segments, According to Findings from Decision Resources Group BURLINGTON,
Presentations include first Phase 2 results evaluating investigational compound Veliparib in patients with non-small cell lung cancer NORTH CHICAGO, Ill., Sept.
Women with mutations in the PALB2 gene have on average a one in three chance of developing breast cancer by the age of seventy.
Around a quarter of smokers who carry a defect in the BRCA2 gene will develop lung cancer at some point in their lifetime.
The Most Promising Emerging Agents in Development for Triple Negative Breast Cancer Target Only Specific Patient Subsets, According to Findings from Decision Resources Group BURLINGTON, Mass.,
- A handkerchief.
- In general, any miraculous portrait of Christ.